eyecro and NeuMedics announce collaboration to utilize MiDROPS™ technology for the development of NM108

Oklahoma City, OK, and Seattle, WA; (May 4, 2015) – eyecro LLC and NeuMedics Inc., today announced the formation of a collaboration to facilitate development of NM108, a first-in-class small molecule to treat a number of ophthalmic disorders that lead to blindness, including Diabetic Retinopathy. The collaboration grants NeuMedics full access to the MiDROPS™ formulation platform developed by eyecro, which can deliver drugs to the front and back of the eye via a topical eyedrop.

Read the entire article here.

Similar Posts